Aptamers are single-stranded, short DNA molecules or RNA that attach to specific molecules, like small molecules or proteins with high affinity and sensitivity. Aptamers have a variety of applications across a range of fields, such as therapeutics, diagnostics and research. They have the ability to bind with remarkable binding affinity and specificity to a particular target, often compared with “artificial antibody.” The process of selecting the aptamers involves an iterative, in vitro procedure which alternates binding and amplification steps to determine Aptamers from a vast library of oligonucleotides that includes distinct sequences. The target is blended with the library and a partitioning process is carried out to distinguish targets bound sequences from those which remain unbound. There are a variety of techniques, including the filtration process, chromatography and centrifugation are used for partitioning. The sequences that are bound towards the targeted are amplified with PCR and the resultant pool is then combined with target, but this time with a higher selection pressure. The process is repeated repeatedly, resulting in the persistence of the most powerful binding agents from million of the sequences. Aptamers are identified by the sequencing.
Aptamers and Biotechnology Medicine The Motor for Innovation
The rise of the market for aptamers can be attributed to a variety of significant reasons. They are used extensively in the fields of biotechnology and pharmaceutical research which is enabling advances in development and discovery of drugs diagnostics, as well as therapeutic treatments. Diagnostic and pathology labs favor the use of aptamer-based diagnostic products to diagnose diseases at the level of cellular. This preference is based on the small size, impressive particularity, precision and efficiency of the aptamers. This is why the rising prevalence of illnesses such as cancer, cardiovascular diseases (CVD) along with age-related macular deterioration (AMD) could result in more patients seeking diagnostic tests in these laboratories. This in turn increases the demand for diagnostics based on aptamers. For instance.
The month of June, 2023 was the time when Aptamer Group and Neuro-Bio came together to work in the creation for a test to detect to detect Alzheimer’s disease. They announced the success of the creation of Optimer Binders that focus on a new Alzheimer’s biomarker for Alzheimer’s disease. The binders could aid in the development of an lateral flow test to aid in earlier detection of Alzheimer’s.
Aptamers can also be used to be linked to drugs, acting as delivery systems for drugs. They’ve been paired with chemotherapy drugs to focus on and bind to cancerous cells, while protecting healthy tissues. In addition, their advantages, like a lower risk of unwanted immune reactions, high thermal stability and efficiency, as well as their cost-effectiveness are expected to increase demand for Aptamers. Aptamers are generally produced by an approach called Systematic Evolution of Ligands by Exponential Enrichment (SELEX) that can be lengthy and require multiple procedures. To overcome this issue, Vivonics Inc., an medical device manufacturer has invented and registered an efficient one-step process called RIDA, which stands for Rapid Isolation Of DNA Aptamers (RIDA) to isolate high-affinity and highly specific aptamers. These advancements are expected to encourage the use of Aptamers.
Multiple Applications and Benefits of Aptamers over Antibodies Drives the Demand
The market for aptamers is experiencing significant growth, driven by the growing awareness of the benefits of aptamers over antibodies. Although antibodies aren’t without their flaws in the field of target small molecules, Aptamers do better in this area. Aptamers, which are short DNA molecules or RNA molecules have high affinity and specificity for a variety of molecules that are targeted, such as small compounds, proteins and even cells. Aptamers exhibit superior performance in adhesion to tiny molecules as well as dyes, which makes them adaptable to use in conventional diagnostic kits and increasing their use to diagnostics at the point of care. This growth is expected to increase the value of their market and encourage greater acceptance of aptamers, both for medical and diagnostic uses. Aptamers are also able to bind larger molecules, specifically proteins, which make up around 98 percent of the molecules. This can facilitate the identification of biomarkers and also the development for diagnostic tests.
Contrary to antibodies, which are typically created by stimulating some kind of immune reaction in models from animals, or by Recombinant DNA technology, aptamers are able to be produced using low-cost chemical techniques. Thus, aptamers provide an attractive option for development of new diagnostic and therapeutic drugs. In addition, antibodies face difficulties in the treatment of neurodegenerative diseases like Alzheimer’s, due to the brain-blood barrier. While technological advances have largely addressed that issue, efficacy of antibodies in treating these diseases is still limited. However, aptamers are short oligonucleotides that can penetrate the blood-brain barrier and offer the possibility of neurodegenerative disorder treatment. For instance,
The month of July, 2023 saw Zentek as well as McMaster revealed positive results for their aptamer-based technology that is exclusive licensed by McMaster University. Their aptamer platform has proven positive results as a preventative or therapeutic agent against SARS-CoV-2 in animal pre-clinical trials. Dr. Li’s aptamers, that were developed after repeated tests showed comparable efficacy against SARS-CoV-2 if contrasted with a monoclonal commercial antibody, suggesting their potential in fighting the virus.
In addition there is the possibility that antibodies create an immune response within the host, which could lead to severe adverse effects. However, Aptamers are not immune-related and are therefore safer. They have numerous advantages, like the ease of designing and synthesis with high efficiency, which makes them an affordable option. Athletes also have lower immunegenicity and facilitate rapid development. The increasing awareness of these advantages has prompted studies and research efforts which has led to a wide range of applications in different areas and a bright future for aptamers within the marketplace.
This North American region holds a substantial share of the global market for aptamers. This is due to the increasing prevalence of chronic illnesses and the presence of major market players, advances in the development of aptamer-based therapies and products as well as a concentration on the discovery of new drugs and development. The established healthcare infrastructure of the region and accessibility are also contributing to its dominant position in the market for aptamers.
The Asia-Pacific region is growing rapidly due to the increasing healthcare infrastructure, the increase in research and development in aptamers, and the increasing emphasis on development and discovery of new drugs within biotech and pharmaceutical firms.
Landscape of the Competitive Landscape
The major players that compete in the world market for aptamers include SomaLogic, Aptamer Group, Aptadel Therapeutics, Base Pair Biotechnologies, Vivonics Inc., Aptagen LLC, TriLink Biotechnologies, Novaptech, NeoVentures Biotechnology Inc., Noxxon Pharma and Aptagen LLC among others.
Organic as well as Inorganic Growth Strategies adopted by the players to establish their Position on the Market
Players that are active in this sector are implementing both organic and inorganic growth strategies, such as acquisitions, collaborations and partnerships to increase market share. For example,
The month of July, 2022 was the time that SomaLogic has made a statement regarding its purchase of Palamedrix, Inc. This acquisition adds an array of engineering and scientific expertise and advanced miniaturization technologies and enhanced user-friendliness capabilities into SomaLogic’s portfolio of. These assets will play a key role in the creation new versions of SomaScan(r) Assay and will further expand its reach into San Diego, California, which will contribute to the overall expansion and capabilities in science.
The market is predicted to expand due to the rising use of aptamers for the development and discovery of drugs as well as a significant increase in the amount of R&D invested in aptamers as well as the aggressive organic and nonorganic growth strategies adopted by companies.
Sources: Medi-Tech Insights Analysis, Expert Interviews
For more granular insights, please get in touch at https://meditechinsights.com/contact-us/
